Drug Shortage Report for REVIA
Report ID | 215710 |
Drug Identification Number | 02213826 |
Brand name | REVIA |
Common or Proper name | REVIA 50MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NALTREXONE HYDROCHLORIDE |
Strength(s) | 50MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 50 |
ATC code | N07BB |
ATC description | DRUGS USED IN ADDICTIVE DISORDERS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-01-10 |
Estimated end date | 2024-02-10 |
Actual end date | 2024-02-12 |
Shortage status | Resolved |
Updated date | 2024-02-13 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2024-01-11 | English | Compare |
v2 | 2024-01-11 | French | Compare |
v3 | 2024-01-25 | English | Compare |
v4 | 2024-01-25 | French | Compare |
v5 | 2024-02-08 | English | Compare |
v6 | 2024-02-08 | French | Compare |
v7 | 2024-02-12 | English | Compare |
v8 | 2024-02-12 | French | Compare |
v9 | 2024-02-13 | English | Compare |
Showing 1 to 9 of 9